{
    "ticker": "IMCR",
    "name": "Imara Inc.",
    "description": "Imara Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with sickle cell disease and other hemoglobin disorders. Founded in 2016, Imara is focused on creating innovative solutions that address the unmet medical needs of these patients, who often face significant health challenges due to their condition. The company's lead product candidate, IMR-687, is an oral therapy designed to enhance the efficacy of existing treatments by targeting the underlying pathophysiology of sickle cell disease. Imara's research and development efforts are driven by a commitment to improving the quality of life for individuals suffering from these debilitating conditions. The company's pipeline includes additional candidates aimed at treating both sickle cell disease and beta-thalassemia, showcasing its dedication to advancing care in the hematology space. Imara's vision is to transform the lives of patients through innovative therapies that not only manage but also potentially cure these genetic disorders.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boston, Massachusetts, USA",
    "founded": "2016",
    "website": "https://www.imara.com",
    "ceo": "Dr. Ameet K. Mistry",
    "social_media": {
        "twitter": "https://twitter.com/imara_inc",
        "linkedin": "https://www.linkedin.com/company/imara-inc/"
    },
    "investor_relations": "https://investors.imara.com",
    "key_executives": [
        {
            "name": "Dr. Ameet K. Mistry",
            "position": "CEO"
        },
        {
            "name": "Michael J. Marcellin",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "IMR-687"
            ]
        }
    ],
    "seo": {
        "meta_title": "Imara Inc. | Innovating Sickle Cell Disease Treatments",
        "meta_description": "Imara Inc. is focused on developing novel therapies for sickle cell disease and other hemoglobin disorders. Learn more about our innovative solutions and commitment to patient care.",
        "keywords": [
            "Imara",
            "Sickle Cell Disease",
            "Biopharmaceuticals",
            "IMR-687",
            "Hematology"
        ]
    },
    "faq": [
        {
            "question": "What is Imara known for?",
            "answer": "Imara is known for developing novel therapies for sickle cell disease and other hemoglobin disorders."
        },
        {
            "question": "Who is the CEO of Imara?",
            "answer": "Dr. Ameet K. Mistry is the CEO of Imara Inc."
        },
        {
            "question": "Where is Imara headquartered?",
            "answer": "Imara is headquartered in Boston, Massachusetts, USA."
        },
        {
            "question": "What is IMR-687?",
            "answer": "IMR-687 is Imara's lead product candidate designed to treat sickle cell disease."
        },
        {
            "question": "When was Imara founded?",
            "answer": "Imara was founded in 2016."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO",
        "BLUE"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}